{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T20:29:52Z","timestamp":1788640192067,"version":"build-2803163510"},"reference-count":61,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007414","name":"Deanship of Graduate Studies and Scientific Research, Qassim University, Saudi Arabia","doi-asserted-by":"publisher","award":["QU-J-PG-2-2025-53795"],"award-info":[{"award-number":["QU-J-PG-2-2025-53795"]}],"id":[{"id":"10.13039\/501100007414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007414","name":"Deanship of Graduate Studies and Scientific Research, Qassim University, Saudi Arabia","doi-asserted-by":"publisher","award":["1446 AH\/2024 AD"],"award-info":[{"award-number":["1446 AH\/2024 AD"]}],"id":[{"id":"10.13039\/501100007414","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Background: Clozapine (CLZ) is an atypical antipsychotic mainly prescribed for treatment-resistant schizophrenia. Beyond psychotic symptoms, patients often exhibit persistent cognitive impairments across domains such as attention, learning, and memory. The mechanisms by which CLZ may influence cognition and provide neuroprotection are not fully elucidated. Accordingly, this study examined how CLZ modulates lipopolysaccharide (LPS)-induced neurotoxicity in rats. Method: Rats were administered LPS to induce cognitive impairment and subsequently treated with CLZ. Behavioral assessments were performed using maze tests (elevated plus-maze (EPM), novel object recognition (NOR), and Y-maze). Biochemical analyses included cholinergic function (acetylcholine (ACh)), neurodegeneration-associated enzymes (glycogen synthase kinase-3 beta (GSK-3\u03b2), \u03b2-site amyloid precursor protein cleaving enzyme-1 (BACE-1), and dipeptidyl peptidase-4 (DPP-4)), oxidative stress markers (lipid Peroxidation (LPO), catalase, and reduced glutathione (GSH)), and apoptotic proteins (B-cell lymphoma-2 (Bcl-2), Bcl-2-associated X protein (Bax), and cleaved Caspase-3 (c-Caspase-3)). Results: CLZ treatment markedly improved performance in EPM, NOR, and Y-maze tasks, indicating recovery of cognitive function in LPS-exposed rats. At the molecular level, CLZ enhanced ACh levels, upregulated the anti-apoptotic protein Bcl-2, and restored antioxidant defenses (catalase and GSH). Conversely, CLZ reduced LPS-induced neurotoxicity by lowering GSK-3\u03b2 activity, LPO, and pro-apoptotic markers (Bax and c-Caspase-3). Conclusion: The findings demonstrate that CLZ exerts neuroprotective effects in an LPS-induced rat model, improving cognition through modulation of cholinergic transmission, oxidative stress, and apoptosis pathways. These results clarify key mechanistic pathways through which CLZ may exert cognitive benefits and highlight its potential relevance for improving schizophrenia-related cognitive dysfunction. Further molecular studies are warranted to confirm and extend these observations toward clinical translation.<\/jats:p>","DOI":"10.3390\/life16020315","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:48:34Z","timestamp":1770889714000},"page":"315","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clozapine Mitigates Lipopolysaccharide-Induced Cognitive Dysfunction by Modulating Cholinergic Function, Oxidative Stress, and Apoptotic Signaling in Rats"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8440-8366","authenticated-orcid":false,"given":"Vasudevan","family":"Mani","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.","family":"Almatrafi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e301097","DOI":"10.1136\/bmjment-2024-301097","article-title":"Severe psychiatric disorders are associated with increased risk of dementia","volume":"27","author":"Legge","year":"2024","journal-title":"BMJ Ment. Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"152415","DOI":"10.1016\/j.comppsych.2023.152415","article-title":"Neurobiology of psychosis and schizophrenia 2022: Nottingham meeting","volume":"127","author":"Sami","year":"2023","journal-title":"Compr. Psychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1017\/S0033291722002781","article-title":"Non-affective psychotic disorders and risk of dementia: A systematic review and meta-analysis","volume":"52","author":"Miniawi","year":"2022","journal-title":"Psychol. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/s41380-023-01949-9","article-title":"Cognitive impairment in schizophrenia: Aetiology, pathophysiology, and treatment","volume":"28","author":"McCutcheon","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Lagan\u00e0, V., Bruno, F., Altomari, N., Bruni, G., Smirne, N., Curcio, S., Mirabelli, M., Colao, R., Puccio, G., and Frangipane, F. (2022). Neuropsychiatric or Behavioral and Psychological Symptoms of Dementia (BPSD): Focus on prevalence and natural history in Alzheimer\u2019s disease and frontotemporal dementia. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.832199"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.31887\/DCNS.2003.5.1\/fmuellerspahn","article-title":"Behavioral disturbances in dementia","volume":"5","year":"2003","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"14138","DOI":"10.1038\/s41598-022-18470-8","article-title":"Impact of behavioral and psychological symptoms of Alzheimer\u2019s disease on caregiver outcomes","volume":"12","author":"Pinyopornpanish","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3233\/JAD-231363","article-title":"Psychosis in neurodegenerative dementias: A systematic comparative review","volume":"99","author":"Cressot","year":"2024","journal-title":"J. Alzheimers Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3233\/JAD-240328","article-title":"Exploring psychosis in neurodegenerative dementia: Connecting symptoms to neurobiology","volume":"99","author":"Morrow","year":"2024","journal-title":"J. Alzheimers Dis."},{"key":"ref_10","first-page":"CD013304","article-title":"Antipsychotics for agitation and psychosis in people with Alzheimer\u2019s disease and vascular dementia","volume":"12","author":"Dichter","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1038\/s41380-025-03023-y","article-title":"Cholinergic system in schizophrenia: A systematic review and meta-analysis","volume":"30","author":"MacDonald","year":"2025","journal-title":"Mol. Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/B978-0-443-19088-9.00005-6","article-title":"The involvement of the cholinergic system in Alzheimer disease","volume":"Volume 211","author":"Cuello","year":"2025","journal-title":"Handbook of Clinical Neurology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1038\/ncomms4925","article-title":"Modulation of dopamine release in the striatum by physiologically relevant levels of nicotine","volume":"5","author":"Wang","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1111\/j.1447-0594.2010.00588.x","article-title":"Acetylcholine-dopamine balance hypothesis in the striatum: An update","volume":"10","author":"Aosaki","year":"2010","journal-title":"Geriatr. Gerontol. Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.11.016","article-title":"Glycogen synthase kinase-3 (GSK-3): Regulation, actions, and diseases","volume":"148","author":"Beurel","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13195-020-00686-3","article-title":"\u03b2-Secretase-1 biological markers for Alzheimer\u2019s disease: State-of-the-art of validation and qualification","volume":"12","author":"Hampel","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Jiang, X., Li, J., Yao, X., Ding, H., Gu, A., and Zhou, Z. (2024). Neuroprotective effects of dipeptidyl peptidase-4 inhibitor on Alzheimer\u2019s disease: A narrative review. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1361651"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1017\/S1461145707008401","article-title":"Oxidative stress in psychiatric disorders: Evidence base and therapeutic implications","volume":"11","author":"Ng","year":"2008","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Trofin, D.M., Sardaru, D.P., Trofin, D., Onu, I., Tutu, A., Onu, A., Oni\u021b\u0103, C., Galaction, A.I., and Matei, D.V. (2025). Oxidative stress in brain function. Antioxidants, 14.","DOI":"10.3390\/antiox14030297"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e70133","DOI":"10.1002\/jbt.70133","article-title":"Oxidative\/nitrosative stress, apoptosis, and redox signaling: Key players in neurodegenerative diseases","volume":"39","year":"2025","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/bs.apha.2017.09.009","article-title":"Unique effects of clozapine: A pharmacological perspective","volume":"Volume 82","author":"Khokhar","year":"2018","journal-title":"Advances in Pharmacology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2019.04.009","article-title":"Neuroprotective effects of the second-generation antipsychotics","volume":"208","author":"Chen","year":"2019","journal-title":"Schizophr. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11481-011-9309-0","article-title":"Clozapine protects dopaminergic neurons from inflammation-induced damage by inhibiting microglial overactivation","volume":"7","author":"Hu","year":"2012","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2174\/1570159X22666231128101725","article-title":"Immunomodulatory effects of clozapine: More than just a side effect in schizophrenia","volume":"22","author":"Amerio","year":"2024","journal-title":"Curr. Neuropharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"173821","DOI":"10.1016\/j.pbb.2024.173821","article-title":"Adjunctive clozapine with bright light mitigates cognitive deficits by synaptic plasticity and neurogenesis in sub-chronic MK-801-treated mice","volume":"243","author":"Zhang","year":"2024","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.brainres.2004.07.009","article-title":"Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: Role of 5-HT1A receptor agonism","volume":"1023","author":"Chung","year":"2004","journal-title":"Brain Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Gass\u00f3, P., Mart\u00ednez-Pinte\u00f1o, A., Rodr\u00edguez, N., Madero, S., G\u00f3mez, M., Segura, A.G., Garc\u00eda-Rizo, C., Mor\u00e9n, C., Mas, S., and Parellada, E. (2023). Neurotoxic\/neuroprotective effects of clozapine and the positive allosteric modulator of mGluR2 JNJ-46356479 in human neuroblastoma cell cultures. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032054"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Arfeen, M., Dhaked, D.K., and Mani, V. (2025). Multipotent effect of clozapine on lipopolysaccharide-induced acetylcholinesterase, cyclooxygenase-2, 5-lipoxygenase, and caspase-3: In vivo and molecular modeling studies. Molecules, 30.","DOI":"10.3390\/molecules30020266"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1111\/bph.15193","article-title":"The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research","volume":"177","author":"Hurst","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Mani, V., and Arfeen, M. (2024). Betahistine\u2019s neuroprotective actions against lipopolysaccharide-induced neurotoxicity: Insights from experimental and computational studies. Brain Sci., 14.","DOI":"10.3390\/brainsci14090876"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"115448","DOI":"10.1016\/j.fct.2025.115448","article-title":"Montelukast\u2019s potential as a neuroprotective agent against acrylamide-induced neurotoxicity: In vivo and computational modelling","volume":"201","author":"Alshammari","year":"2025","journal-title":"Food Chem. Toxicol."},{"key":"ref_32","first-page":"371","article-title":"Understanding the neurobiological mechanisms of LPS-induced memory impairment","volume":"84","author":"Golkar","year":"2025","journal-title":"Acta Neurobiol. Exp."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s12035-015-9636-x","article-title":"Clozapine improves memory impairment and reduces A\u03b2 level in the Tg-APPswe\/PS1dE9 mouse model of Alzheimer\u2019s disease","volume":"54","author":"Choi","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Ilg, A.K., Enkel, T., Bartsch, D., and B\u00e4hner, F. (2018). Behavioral effects of acute systemic low-dose clozapine in wild-type rats: Implications for the use of DREADDs in behavioral neuroscience. Front. Behav. Neurosci., 12.","DOI":"10.3389\/fnbeh.2018.00173"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.31083\/j.jin2102049","article-title":"Investigation of the optimal dose for experimental lipopolysaccharide-induced recognition memory impairment: Behavioral and histological studies","volume":"21","author":"Alzahrani","year":"2022","journal-title":"J. Integr. Neurosci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/FBP.0000000000000200","article-title":"LASSBio-579, a prototype antipsychotic drug, and clozapine are effective in the novel object recognition task, a recognition memory model","volume":"27","author":"Antonio","year":"2016","journal-title":"Behav. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.pbb.2011.06.011","article-title":"Effects of olanzapine, sertindole and clozapine on MK-801-induced visual memory deficits in mice","volume":"99","author":"Mutlu","year":"2011","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bbr.2014.06.012","article-title":"Clozapine and glycinamide prevent MK-801-induced deficits in the novel object recognition test in the domestic rabbit (Oryctolagus cuniculus)","volume":"271","author":"Hoffman","year":"2014","journal-title":"Behav. Brain Res."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Bahaidrah, K.A., Alzahrani, N.A., Aldhahri, R.S., Mansouri, R.A., and Alghamdi, B.S. (2022). Effects of different lipopolysaccharide doses on short- and long-term spatial memory and hippocampus morphology in an experimental Alzheimer\u2019s disease model. Clin. Transl. Neurosci., 6.","DOI":"10.3390\/ctn6030020"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/sj.npp.1300669","article-title":"Reversal of clozapine effects on working memory in rats with fimbria-fornix lesions","volume":"30","author":"Addy","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Chen, Z.R., Huang, J.B., Yang, S.L., and Hong, F.F. (2022). Role of cholinergic signaling in Alzheimer\u2019s disease. Molecules, 27.","DOI":"10.3390\/molecules27061816"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Carnac, T. (2022). Schizophrenia hypothesis: Autonomic nervous system dysregulation of fetal and adult immune tolerance. Front. Syst. Neurosci., 16.","DOI":"10.3389\/fnsys.2022.844383"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1038\/s41386-021-01070-x","article-title":"Lower cholinergic basal forebrain volumes link with cognitive difficulties in schizophrenia","volume":"46","author":"Avram","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e14818","DOI":"10.1111\/cns.14818","article-title":"GSK3: A potential target and pending issues for treatment of Alzheimer\u2019s disease","volume":"30","author":"Zhao","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.3233\/JAD-2012-129025","article-title":"GSK3 and tau: Two convergence points in Alzheimer\u2019s disease","volume":"33","author":"Hernandez","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.neuro.2020.12.016","article-title":"Cognitive effects of the GSK-3 inhibitor lithium in an LPS\/chronic mild stress rat model of depression: Hippocampal and cortical neuroinflammation and tauopathy","volume":"83","author":"Ebeid","year":"2021","journal-title":"Neurotoxicology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1523\/JNEUROSCI.4396-06.2007","article-title":"\u03b2-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: Implications for Alzheimer\u2019s disease pathogenesis","volume":"27","author":"Zhao","year":"2007","journal-title":"J. Neurosci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"102476","DOI":"10.1016\/j.arr.2024.102476","article-title":"Recent advancement in understanding of Alzheimer\u2019s disease: Risk factors, subtypes, and drug targets and potential therapeutics","volume":"101","author":"Prabha","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"164","DOI":"10.35772\/ghm.2024.01033","article-title":"BACE1 inhibitor drugs for the treatment of Alzheimer\u2019s disease: Lessons learned, challenges to overcome, and future prospects","volume":"6","author":"Ghosh","year":"2024","journal-title":"Glob. Health Med."},{"key":"ref_50","first-page":"e72648","article-title":"Exploring the therapeutic potential of DPP4 inhibitors in Alzheimer\u2019s disease: Molecular insight and clinical outcome","volume":"16","author":"Sulangi","year":"2024","journal-title":"Cureus"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Kim, S., Jung, U.J., and Kim, S.R. (2024). Role of oxidative stress in blood\u2013brain barrier disruption and neurodegenerative diseases. Antioxidants, 13.","DOI":"10.3390\/antiox13121462"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Dos Santos, M.P., Leocadio, V.E., de S\u00e1 Hayashide, L., Marques, M., Carvalho, C.F., Galina, A., and Diniz, L.P. (2025). Lipopolysaccharide induces mitochondrial fragmentation and energetic shift in reactive microglia: Evidence for a cell-autonomous program of metabolic plasticity. Toxins, 17.","DOI":"10.3390\/toxins17060293"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"9613090","DOI":"10.1155\/2019\/9613090","article-title":"Role of catalase in oxidative stress- and age-associated degenerative diseases","volume":"2019","author":"Nandi","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Aoyama, K. (2021). Glutathione in the brain. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22095010"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Essadek, S., Bouchab, H., El Kebbaj, R., Gondcaille, C., El Kamouni, S., Savary, S., Vamecq, J., Essamadi, A., Cherkaoui-Malki, M., and Nasser, B. (2022). Effects of a short-term lipopolysaccharide challenge on mouse brain and liver peroxisomal antioxidant and \u03b2-oxidative functions: Protective action of argan oil. Pharmaceuticals, 15.","DOI":"10.3390\/ph15040465"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"20221051","DOI":"10.1515\/biol-2022-1051","article-title":"Neurodegenerative diseases and neuroinflammation-induced apoptosis","volume":"20","author":"Huang","year":"2025","journal-title":"Open Life Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.tcb.2008.01.007","article-title":"How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?","volume":"18","author":"Chipuk","year":"2008","journal-title":"Trends Cell Biol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Nguyen, T.T.M., Gillet, G., and Popgeorgiev, N. (2021). Caspases in the developing central nervous system: Apoptosis and beyond. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.702404"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41392-025-02176-0","article-title":"The BCL2 family: From apoptosis mechanisms to new advances in targeted therapy","volume":"10","author":"Vogler","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1176\/appi.ajp.2012.12030342","article-title":"Atypical antipsychotic use in patients with dementia: Managing safety concerns","volume":"169","author":"Steinberg","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"340","DOI":"10.4212\/cjhp.3390","article-title":"Clozapine for management of neuropsychiatric symptoms in dementia with Lewy Bodies: Case report and literature review","volume":"764","author":"Hashemi","year":"2023","journal-title":"Can. J. Hosp. Pharm."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/2\/315\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:15:45Z","timestamp":1770891345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/2\/315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":61,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["life16020315"],"URL":"https:\/\/doi.org\/10.3390\/life16020315","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]}}}